Karolinska University Hospital

Researchers

• ANAnn Nordgren
• AHAnna Karin Hedström
• ANAnna Skarin Nordenvall

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation

  NCT07899918· Karolinska University Hospital· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.

  NCT07480395· W.L.Gore & Associates· Source

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

  NCT07584967· Phase 2· AnaCardio AB· Source

• Not yet recruiting

  Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)

  NCT07883356· Phase 2· Region Skane· Source

• Recruiting

  FLAsH-IV-AML: A study evaluating the safety and effectiveness of adding hydroxyurea to treatment for adults with acute myeloid leukemia (AML) that has relapsed after treatment or has not responded to treatment

  2026-526961-76-00· Phase 1/2· Karolinska University Hospital· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

  2025-524722-17-00· Phase 4· Region Skane· Source

• Recruiting

  Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation

  NCT07424690· Karolinska University Hospital· Source

• Recruiting

  Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

  NCT07473843· Phase 3· Arrowhead Pharmaceuticals· Source

• Recruiting

  Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

  NCT07219238· Phase 2/3· GE Healthcare· Source

• Not yet recruiting

  Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia

  NCT07766850· Phase 1/2· Christer C Nilsson· Source

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

  NCT07843472· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

  NCT01491815· Phase 4· Karolinska Institutet· Source

• Not yet recruiting

  REcovery After Cancer Application

  NCT07642492· Karolinska Institutet· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Ole Schmeltz Søgaard· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Not yet recruiting

  Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma

  2026-526821-16-00· Phase 1/2· Karolinska University Hospital· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

  2025-524793-42-00· Phase 2· Janssen Cilag International· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-524711-36-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

  2025-523912-35-00· Phase 3· Alkermes Inc.· Source

• Not yet recruiting

  COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

  2026-526122-41-00· Phase 2· Uppsala University Hospital· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

  NCT07514858· Phase 2· H. Lundbeck A/S· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-523911-13-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· OncoZenge AB· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Recruiting

  Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

  2024-516896-34-00· Phase 1/2· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· The POLG Foundation· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· Phase 3· argenx· Source

• Not yet recruiting

  A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

  2024-515627-10-00· Phase 1/2· Bonsai Biotherapeutics AB· Source

• Not yet recruiting

  A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

  NCT07455422· University Hospital, Antwerp· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Anti-B-cell therapy in RA-ILD

  2025-524872-51-00· Phase 4· Vaestra Goetalandsregionen· Source

• Recruiting

  A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients

  NCT07839793· Phase 4· Navamedic AB· Source

• Recruiting

  Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment

  2025-524022-18-00· Phase 2· Vaestra Goetalandsregionen· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  REPO-HYPER II

  2024-520231-33-00· Phase 2· Karolinska University Hospital· Source

Showing 50 of 474.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers39 recruiting
• Colorectal cancer18 recruiting
• Acute myeloid leukaemia17 recruiting
• Lung cancer16 recruiting
• Heart failure15 recruiting
• Pancreatic cancer15 recruiting
• Melanoma13 recruiting
• Prostate cancer12 recruiting
• Atrial fibrillation11 recruiting
• Gastric and oesophageal cancer11 recruiting
• Multiple myeloma10 recruiting
• Sarcoma10 recruiting
• Stroke9 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Chronic kidney disease8 recruiting
• Liver and biliary tract cancer8 recruiting
• Crohn's disease7 recruiting
• Obesity7 recruiting
• Ovarian cancer7 recruiting
• Rheumatoid arthritis7 recruiting
• Aortic aneurysm6 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• High blood pressure6 recruiting
• Ulcerative colitis6 recruiting
• Cerebral palsy5 recruiting
• Cervical cancer5 recruiting
• Head and neck cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Multiple sclerosis5 recruiting
• Myelodysplastic syndromes5 recruiting
• Coronary artery disease4 recruiting
• Endometrial cancer4 recruiting
• Kidney cancer4 recruiting
• Parkinson disease4 recruiting
• Amyloidosis3 recruiting
• Bladder cancer3 recruiting
• Cystic fibrosis3 recruiting
• Graves' disease and hyperthyroidism3 recruiting
• Liver cirrhosis3 recruiting
• Narcolepsy3 recruiting
• Alzheimer disease2 recruiting
• ANCA-associated vasculitis2 recruiting
• Aortic stenosis2 recruiting
• Barrett's oesophagus2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Familial hypercholesterolaemia2 recruiting
• Follicular lymphoma2 recruiting
• Glioblastoma2 recruiting
• Haemophilia2 recruiting
• HIV2 recruiting
• Hodgkin lymphoma2 recruiting
• Lupus (SLE)2 recruiting
• Mantle cell lymphoma2 recruiting
• Myasthenia gravis2 recruiting
• Neuroblastoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Peripheral artery disease2 recruiting
• Sarcoidosis2 recruiting
• Thyroid cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 2 diabetes2 recruiting
• ALS (motor neurone disease)1 recruiting
• Ankylosing spondylitis1 recruiting
• Asthma1 recruiting
• Bronchiectasis1 recruiting
• COPD1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Huntington's disease1 recruiting
• Hydrocephalus1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Insomnia1 recruiting
• Lewy body dementia1 recruiting
• Long COVID and ME/CFS1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Myocarditis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Osteoarthritis1 recruiting
• Polycystic ovary syndrome1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Tuberculosis1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  Simultaneous T2-FLAIR and T1 Brain MRI With ENRAGED FLAIR in Multiple Sclerosis

  NCT07687693· Region Stockholm· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Muscle Function in Patients With Single-chamber Heart

  NCT07420660· Karolinska Institutet· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

  2024-514745-10-00· Phase 1· Pfizer Inc.· Source

• Active, not recruiting

  Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

  NCT06940830· Phase 4· Swedish Orphan Biovitrum· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· Phase 1· AbbVie· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

  NCT06544733· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patients with Metastatic Breast Cancer

  2023-507720-23-00· Phase 1/2· GE Healthcare Limited· Source

• Active, not recruiting

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· Phase 2· Sanofi· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

  2024-516969-36-00· Phase 1/2· Dextech Medical AB· Source

• Completed

  The Knowledge About the Underlying Cause of Hearing Loss in Children

  NCT07303426· Karolinska Institutet· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to conventional staging in women with presumed early-stage endometrial cancer.

  2023-505991-31-00· Phase 3· Karolinska University Hospital· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

  NCT06195930· Phase 2· Bayer· Source

• Completed

  Hemodynamic Effects of Apnoeic Oxygenation With High-flow Nasal Oxygen in Adults Undergoing Laryngeal Surgery

  NCT06316063· Region Stockholm· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

  NCT05979311· Phase 3· ViiV Healthcare· Source

• Completed

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· Phase 2· Organon LLC· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05995353· Phase 3· AbbVie· Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Phase 3· Alector Inc.· Source

• Completed

  Introduction of EndoSign ® in Management of Barrett's Oesophagus - a Swedish Feasibility Study

  NCT07036432· Vastra Gotaland Region· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Completed

  Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

  NCT06020014· Phase 2· AstraZeneca· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study of RBD1016 in CHB Participants

  NCT05961098· Phase 2· Suzhou Ribo Life Science Co. Ltd.· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitis

  2023-503880-40-00· Phase 2· Suzhou Ribo Life Science Co. Ltd.· Source

• Completed

  Carry Life@ UF System Clinical Study

  NCT05874804· Triomed AB· Source

• Enrolling by invitation

  A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

  NCT05979441· Phase 3· argenx· Source

• Completed

  A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

  NCT05958407· Phase 3· LEO Pharma· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

  NCT05742269· Karolinska University Hospital· Source

• Completed

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source

• Completed

  A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

  NCT05891496· Phase 3· Novo Nordisk A/S· Source

• Completed

  Brief Internet-delivered CBT After ACS

  NCT05607992· Karolinska Institutet· Source

• Completed

  A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT06087289· Phase 1/2· Novakand Pharma AB· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· AstraZeneca· Source

• Completed

  A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

  NCT05668741· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Phase Ib/IIa Trial With AC01 in Patients With HFrEF

  NCT05642507· Phase 1/2· AnaCardio AB· Source

Showing 50 of 169.

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure145 works · 24 trials
• Alzheimer disease105 works · 15 trials
• Obesity104 works · 9 trials
• Asthma86 works · 6 trials
• Liver and biliary tract cancer74 works · 16 trials
• Lupus (SLE)70 works · 5 trials
• Type 2 diabetes68 works · 4 trials
• Atrial fibrillation67 works · 16 trials
• Rheumatoid arthritis61 works · 9 trials
• Chronic kidney disease61 works · 20 trials
• Multiple sclerosis54 works · 8 trials
• Melanoma50 works · 23 trials
• Fatty liver disease (MASLD/MASH)50 works · 1 trial
• Coronary artery disease45 works · 13 trials
• Gastric and oesophageal cancer44 works · 18 trials
• Epilepsy35 works · 2 trials
• Cervical cancer32 works · 12 trials
• Ovarian cancer29 works · 13 trials
• Pancreatic cancer29 works · 19 trials
• Ulcerative colitis29 works · 12 trials
• Crohn's disease27 works · 14 trials
• Endometrial cancer25 works · 11 trials
• ALS (motor neurone disease)22 works · 4 trials
• Triple-negative breast cancer21 works · 7 trials
• Type 1 diabetes21 works · 4 trials
• Coeliac disease21 works · 0 trials
• Osteoporosis21 works · 0 trials
• Cytomegalovirus infection20 works · 0 trials
• Cerebral palsy19 works · 5 trials
• Hearing loss17 works · 2 trials